These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29099667)

  • 21. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
    Elewski BE; Puig L; Mordin M; Gilloteau I; Sherif B; Fox T; Gnanasakthy A; Papavassilis C; Strober BE
    J Dermatolog Treat; 2017 Sep; 28(6):492-499. PubMed ID: 28266243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management.
    Augustin M; Langenbruch A; Gutknecht M; Reich K; Körber A; Maaßen D; Mrowietz U; Thaçi D; von Kiedrowski R; Radtke MA
    Br J Dermatol; 2018 Dec; 179(6):1385-1391. PubMed ID: 30334253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II).
    Carrascosa JM; Galán M; de Lucas R; Pérez-Ferriols A; Ribera M; Yanguas I
    Actas Dermosifiliogr; 2016 Nov; 107(9):712-729. PubMed ID: 27344068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment goals for moderate to severe psoriasis: an Australian consensus.
    Baker C; Mack A; Cooper A; Fischer G; Shumack S; Sidhu S; Soyer HP; Wu J; Chan J; Nash P; Rawlin M; Radulski B; Foley P
    Australas J Dermatol; 2013 May; 54(2):148-54. PubMed ID: 23330815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER).
    Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M
    J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A statistical method to convert published response rates into marginal distributions with an example application in psoriasis.
    Petto H; Mrowietz U; Wilhelm S; Schacht A
    Pharm Stat; 2019 Jan; 18(1):4-21. PubMed ID: 30259635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.